DialysisPPO Issued Patent for Health Plan Language Limiting Exposure to Costly Dialysis Claims
Language Enables Health Plans to Reduce Dialysis Costs Up to 90%
KING OF PRUSSIA, Pa., June 4, 2013 /PRNewswire/ — DialysisPPO, founded in 2006 to help employer-group health plans (“EGHPs”) manage the high cost of chronic, long-term dialysis – typically for the treatment of End-Stage Renal Disease (“ESRD”) – announced today that the United States Patent and Trademark Office (USPTO) issued a patent covering our dialysis cost containment solution that limits exposure to dialysis claims liability.
EGHP members diagnosed with ESRD must either receive a kidney transplant or undergo a regular course of life-sustaining dialysis treatments. Due to the gravity of this disease, ESRD is the only medical diagnosis in all of American healthcare that entitles a person to Medicare coverage, regardless of their age. Unfortunately for EGHPs, Medicare does not become the primary payer for approximately three years, leaving EGHPs responsible for treatments that can cost in excess of $600,000 per person annually. Our patented plan language enables EGHPs to lower their annual costs by as much as 90%, while at the same time improving the level of benefits for plan members suffering from ESRD. Our typical client saves approximately $485,000 per dialysis case per annum.
Visit DialysisPPO on the Internet at www.dialysisppo.com.
Follow us on LinkedIn at http://www.linkedin.com/company/dialysisppo
Contact: John Brophy President 866.580.1943
This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.